-
The NHS has rejected the Alzheimer's drug donanemab, citing insufficient value for patients despite its recent licensing in the UK. This marks the second disease-modifying Alzheimer's treatment turned down by NICE in months, raising concerns about the UK's position in dementia treatment development.
-
Novo Nordisk's semaglutide, marketed as Ozempic and Wegovy, is poised to become the top-selling drug franchise globally. However, competition from Eli Lilly's Zepbound and other emerging treatments could challenge its dominance. Meanwhile, Smoothie King has launched a new menu catering to users of GLP-1 medications, reflecting the growing popularity of these drugs among Americans.
-
As World Diabetes Day approaches, the accessibility of diabetes treatments remains a pressing issue. With rising cases of type 2 diabetes, particularly among younger populations, the need for affordable insulin pens is critical, especially in low-income countries. Recent corporate decisions further complicate access to essential medications.
-
The weight-loss drug market is evolving with new entrants like Wegovy and Mounjaro gaining traction. Novo Nordisk's Wegovy is now available in China, while Eli Lilly's Mounjaro has been approved in Hong Kong. The competition intensifies as biotech firms develop innovative treatments amid rising demand for obesity management.
-
Recent reports highlight the growing diabetes epidemic in the US, affecting over 38 million people. Concurrently, new weight-loss drugs show promise in prolonging life for those with chronic kidney disease, indicating a potential shift in treatment approaches for these interconnected health issues.